05/12/22 4:14 PMNasdaq : RCEL earningsAVITA Medical Reports First Quarter 2022 Financial ResultsAVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “ Company ”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration forRHEA-AIneutral
05/09/22 4:01 PMNasdaq : RCEL RECELL® System to be Highlighted at Upcoming Music City SCALE Multidisciplinary Dermatology MeetingAVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multipleRHEA-AIneutral
04/28/22 4:01 PMNasdaq : RCEL earningsAVITA Medical to Announce First Quarter 2022 Financial ResultsAVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs,RHEA-AIneutral
04/21/22 9:00 AMNasdaq : RCEL managementAvita Medical, Inc. Announces Resignation of Louis Drapeau from Board of DirectorsAVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multipleRHEA-AIneutral
04/04/22 8:00 AMNasdaq : RCEL RECELL® System Data to be Presented at the American Burn Association Annual MeetingAVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developingRHEA-AIneutral
03/23/22 4:01 PMNasdaq : RCEL clinical trialRECELL® System Vitiligo Clinical Trial Protocol to be Presented at the Global Vitiligo Foundation Annual Scientific SymposiumAVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs,RHEA-AIneutral
03/21/22 4:01 PMNasdaq : RCEL AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL® System in Soft Tissue ReconstructionAVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enablesRHEA-AIneutral
03/02/22 4:01 PMNasdaq : RCEL Avita Medical, Inc. Signs Agreement with Premier, Inc. to Supply the RECELL® System to Hospitals and Health Systems Across the U.S.AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company thatRHEA-AIpositive
02/28/22 4:01 PMNasdaq : RCEL earningsAVITA Medical Reports Quarter Ending December 31, 2021, and Transition Period July 1, 2021, to December 31, 2021, Financial ResultsAVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (the “ Company ”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration forRHEA-AIpositive
02/23/22 4:28 PMNasdaq : RCEL partnershipThe RECELL® System Receives PMDA Approval in Japan and AVITA Medical will Commercialize in Partnership with COSMOTEC, an M3 Group CompanyAVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs,RHEA-AIpositive